Company Profile

Theratome Bio (AKA: Theratome Bio Inc~NeuroFx Inc)
Profile last edited on: 1/10/20      CAGE: 6PV82      UEI:

Business Identifier: Stem cell-based therapeutics
Year Founded
2011
First Award
2015
Latest Award
2019
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1800 North Capitol Street E504G
Indianapolis, IN 46202
   (317) 502-3418
   N/A
   www.theratomebio.com
Location: Single
Congr. District: 07
County: Marion

Public Profile

TheraTomebio - previously dba NeuroFx - is developing an innovative, cell-free therapeutic factor concentrate derived from adult adipose (fat) stem cells (NFx101). Thera-101 (previously NFx101) - an injectable biologic drug designed to be first-line therapy for ischemic brain injury, including stroke - has demonstrated great potential to halt brain injury caused by stroke, promote regeneration and repair of brain tissues, and, most impressively, re-establish normal function in animals. NFx-101 is a platform technology that has potential to be successfully used in non-neurological conditions (e.g., musculoskeletal, dermatologic, cardiovascular) as well. The plan is that NeuroFx will create value in these non-core indications by partnering with biopharmaceutical, regenerative medicine or cosmetic companies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  Michael Coleman -- President and CEO

  Wade Lange -- Former President and CEO

  Brian Johnstone -- Co-Founder, Director of Research and Development

  Keith March -- Chief Medical Director

  Karen S Momper -- Director Business Development